ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Development and validation of a nomogram to predict medication risk based on a knowledge, attitude and practice (KAP) survey of residents in Shanxi Province, China.Frontiers in pharmacology · 2024Article
- Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery.BMC cancer · 2021Article
- A signature of 24 aging‑related gene pairs predict overall survival in gastric cancer.Biomedical engineering online · 2021Article
- Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2021Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
11 authors at 1 institution in 1 country.
R Olofsson BaggeR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Michal KicinskiR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Mark B FariesR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
David E GyorkiR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Karolin IsakssonR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Dimitrios KatsareliasR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Serigne LoR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Marc MoncrieffR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Andrew SpillaneR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Stefan SuciuR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Alexander van AkkooiR. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Sahlgrenska University Hospital · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.